Vis enkel innførsel

dc.contributor.authorNieder, Carsten
dc.contributor.authorPawinski, Adam
dc.contributor.authorAndratschke, H
dc.date.accessioned2014-05-28T08:18:27Z
dc.date.available2014-05-28T08:18:27Z
dc.date.issued2013
dc.description.abstractThe important role of combined chemoradiation for several groups of patients with nonsmall cell lung cancer (NSCLC) is reflected by the large number of scientific articles published during the last 30 years. Different measures of impact and clinical relevance of published research are available, each with its own pros and cons. For this review, article citation rate was chosen. Highly cited articles were identified through systematic search of the citation database Scopus. Among the 100 most often cited articles, meta-analyses (nD5) achieved a median of 203 citations, guidelines (nD7) 97, phase III trials (nD29) 168, phase II trials (nD21) 135, phase I trials (nD7) 88, and others combined 115.5 (p D0.001). Numerous national and international cooperative groups and several single institutions were actively involved in performing often cited, high-impact trials, reflecting the fact that NSCLC is a world-wide challenge that requires research collaboration. Platinum-containing combinations have evolved into a standard of care, typically administered concurrently.The issue of radiotherapy fractionation and total dose has also been studied extensively, yet with less conclusive results. Differences in target volume definition have been addressed. However, it was not possible to test all theoretically possible combinations of radiotherapy regimens, drugs, and drug doses (lower radiosensitizing doses compared to higher systemically active doses).That is why current guidelines offer physicians a choice of different, presumably equivalent treatment alternatives. This review identifies open questions and strategies for further research.en
dc.identifier.citationFrontiers in Oncology 3(2013), s. 176en
dc.identifier.cristinIDFRIDAID 1090779
dc.identifier.doihttp://dx.doi.org/10.3389/fonc.2013.00176
dc.identifier.issn2234-943X
dc.identifier.urihttps://hdl.handle.net/10037/6327
dc.identifier.urnURN:NBN:no-uit_munin_5915
dc.language.isoengen
dc.publisherFrontiersen
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en
dc.titleCombined radio- and chemotherapy for non-small cell lung cancer: systematic review of landmark studies based on acquired citationsen
dc.typeJournal articleen
dc.typeTidsskriftartikkelen
dc.typePeer revieweden


Tilhørende fil(er)

Thumbnail
Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel